Johnson & Johnson is acquiring Firefly Bio for $1 billion in cash to add a degrader antibody platform aimed at hard-to-treat ...
Johnson & Johnson JNJ announced that it has entered into a definitive agreement to acquire California-based biotech, Firefly ...
Under the German "individueller Heilversuch" regulatory framework, the patient received an 11-peptide personalized immunotherapy designed without tumor biopsy, using the patient's HLA genotype and ...
Massive Bio, a global leader in AI-driven precision oncology and clinical trial matching operating across 17+ countries, and ...
ADCs have become a core pillar of cancer treatment as increasingly sophisticated design is translating into stronger efficacy ...
Targeted therapies and immunotherapies offer new treatment options for more types of cancer, but these drugs are less helpful when tumors produce multiple copies of a gene. This gene amplification ...
A machine learning model developed by researchers at the Johns Hopkins Kimmel Cancer Center filters out the biological noise in liquid biopsy samples, helping clinicians better match therapies to ...
Daraxonrasib doubles survival — a RAS‑targeting drug development breakthrough.
This week, I address pushback I received on my Novartis-MorphoSys column. But first, a preview of the expected readout from Gritstone Bio’s neoantigen cancer vaccine study. Before the end of the ...
Stories by SWNS on MSN
“Biological missile” cancer treatment approved by NHS a “breakthrough,” doctor says
Today, the NHS has approved a new ovarian cancer treatment. It’s been tagged a “biological missile” because of the way it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results